De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

MindBio Therapeutics Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Justin Hanka

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	3.4yrs
Eigendom CEO	5.7%
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	3.3yrs

Recente managementupdates

Recent updates

CEO

Justin Hanka (50 yo)

3.4yrs

Tenure

Mr. Justin Adam Hanka, B.Bus, Grad Dip. Fin, serves as Non-Executive Chairman of EYEFI Group Technologies Inc. since December 2022. He was Chairman of Blackhawk Growth Corp. from June 2022 until May 2023 a...

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Justin Hanka	Co Founder	3.4yrs	geen gegevens	5.74% A$ 190.8k
Gavin Upiter	Independent Chairman	3.3yrs	geen gegevens	geen gegevens
Zena Burgess	Independent Non Executive Director	3.3yrs	geen gegevens	geen gegevens

3.3yrs

Gemiddelde duur

54yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van MBIO wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.3 jaar).

MindBio Therapeutics Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Insufficient new directors

Recent updates

MindBio Therapeutics Corp. Announces Sustained Antidepressant Response 3-Months Post Treatment in Microdosing Depression Clinical Trials

Insufficient new directors

Mindbio Therapeutics Reports Secondary Data: Improvement of Psychological Outcomes & Safety Results in Depressed Patients from Phase 2A Depression Trial

MindBio Therapeutics Corp. Begins Phase 2B Take-Home Microdosing (MB22001) Clinical Trial in Patients with Major Depressive Disorder

Mindbio Therapeutics Receives Final Regulatory Approval to Conduct Phase 2B Randomised Controlled Trial Microdosing Mb22001 in Patients Diagnosed with Major Depressive Disorder

MindBio Therapeutics Corp. Announces Positive Depression Data from World-First Phase 2a Take-Home Microdosing Trial

MindBio Therapeutics Corp. Completes World First Take Home Phase 2a Microdosing Depression Trial

MindBio Therapeutics Corp. Announces Completion of Landmark Phase 2A LSD Microdosing (MB22001) Clinical Trial in Distressive Disorder

MindBio Therapeutics Corp. CEO Provides End of Year Video Update on Phase 2 Clinical Trials

MindBio Therapeutics Corp. Begins Dosing MB22001 in World First Phase 2B Microdosing Clinical Trial in Advanced Stage Cancer Patients

Mindbio Therapeutics Corp. Provides Video Update on Phase 2a Depression Trial Using MB22001

MindBio Therapeutics Corp. Announces Tenth Patient with Depression Starts Dosing MB22001 in Take Home Microdosing Trials

MindBio Therapeutics Corp. Announces Major Genetic Discovery in Microdosing Research

MindBio Therapeutics Corp. Begins Dosing Mb22001 in Phase 2 Clinical Trial in World First Take-Home Microdosing Study in Patients with Depression

Mindbio Therapeutics Corp. Receives First Batch of Mb22001 Ready for Take At Home Psychedelic Clinical Trials

MindBio Therapeutics Corp. Starts Pre-Screening for Participant Entry into Phase 2LSD-Microdosing Clinical Trials

MindBio Therapeutics Corp. Announces a Significant Breakthrough Based on Sleep Data Collected During Randomized Controlled Trials of LSD-Microdosing

MindBio Therapeutics Corp. Reports Breakthrough Discovery in Microdosing Clinical Trial Reveals Significant Positive Effects on Quality of Sleep

MindBio Therapeutics Corp. Announces Two Fully Funded Phase 2 LSD-Microdosing Clinical Trials

Mindbio Therapeutics Receives Initial Shipment of 1,000,000 Microdoses of LSD for Phase 2 Clinical Trials for Depression

MindBio Therapeutics Corp. announced that it has received CAD 0.633276 million in funding

CEO

Tenure

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd